Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.35 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | VNN1 | O95497 | 2/20 | 0.34 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GOT1 | P17174 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL444168 | 0.74 | SMN1; SMN2 (0.49) | — | |
| SCHEMBL3150298 | 0.74 | — | — | |
| SCHEMBL8691162 | 0.74 | — | — | |
| SCHEMBL28021265 | 0.73 | CTDSP1 (0.41) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL7310669 | 0.72 | CYP1A2 (0.51) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 | |
| Hydrochloric Acid SCHEMBL27823343 | 0.72 | CTDSP1 (0.41) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL4272781 | 0.71 | CTDSP1 (0.50) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL19764921 | 0.70 | CTDSP1 (0.43) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 | |
| SCHEMBL344825 | 0.70 | — | — | |
| SCHEMBL3076036 | 0.69 | CYP1A2 (0.47) | CTDSP1CYP1A2GABRA1GABRG2GABRB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2540719-B1 | CYCLIC AMINE COMPOUND AND ACARICIDE | NIPPON SODA CO (JP) | 2015-10-07 | — | — | EP | disclosed |
| US-8980912-B2 | Cyclic amine compound and acaricide | NIPPON SODA CO., LTD. (JP) | 2015-03-17 | — | — | US | disclosed |
| EP-2540719-A1 | CYCLIC AMINE COMPOUND AND MITICIDE | Nippon Soda Co., Ltd. (JP) | 2013-01-02 | — | — | EP | disclosed |
| US-20120309964-A1 | CYCLIC AMINE COMPOUND AND ACARICIDE | NIPPON SODA CO., LTD | 2012-12-06 | — | — | US | disclosed |
| CN-102770430-A | Cyclic amine compound and miticide | NIPPON SODA CO | 2012-11-07 | — | — | CN | disclosed |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309964-A1 | CYCLIC AMINE COMPOUND AND ACARICIDE | CYCS, NAT10, CYC1 | CTDSP1 1788/4885CYP1A2 265/4885GABRA1 4453/4885 |
| US-20040019068-A1 | Novel remedies or preventives for angiostenosis | CMA1, ACE, AGTR1 | CTDSP1 1075/4885CYP1A2 2460/4885GABRA1 4066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.